Sub-Q Bionics Secures $1.5M Pre-Seed Funding for Lymphedema Technology Development
Sub-Q Bionics has successfully closed a $1.5 million pre-seed funding round to advance its innovative bionic lymph node technology for lymphedema management. This funding, which includes contributions from Mayo Clinic, Yeda, and private investors, aims to enhance treatment options for millions affected by lymphedema.
Theia Market Signal Identification - AI Assisted
Sub-Q Bionics has raised $1.5 million in a pre-seed funding round to develop a subcutaneous implant for managing lymphedema. The funding involves investments from Mayo Clinic, Yeda Research and Development Company, and matching support from the Israel Innovation Authority.
The bionic lymph node technology aims to improve patients' quality of life by enabling automatic fluid management and reducing symptoms such as swelling and pain. Lymphedema is a significant health concern for millions globally, often affecting breast cancer survivors. The company plans to utilize the funds to accelerate product development, refine regulatory strategies, and prepare for a seed funding round anticipated in Q2 2026.
Comments